The rapid rise of GLP-1 weight-loss drugs has come with a raucous side show—a wave of copycat drugs unbound by drug patents. The knockoff surge was led by Hims & Hers Health, the telehealth firm that ...

The GLP-1 drugmaker recorded $26.0M of net income compared to only $1.2M in Q4 2023, thanks mainly to a ~95% YoY rise in its revenue, which reached $481.1M, exceeding the consensus by $10.6M.